51
|
Casassa E, Riffaud L, Sibaud V, Boulinguez S, Chira C, Gangloff D, Montastruc M, Lamant L, Paul C, Meyer N. [Efficacy of combined paclitaxel/cetuximab in cutaneous squamous-cell carcinoma: A retrospective analysis of 14 patients]. Ann Dermatol Venereol 2020; 147:303-306. [PMID: 32145990 DOI: 10.1016/j.annder.2019.07.009] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/13/2018] [Revised: 11/03/2018] [Accepted: 07/12/2019] [Indexed: 11/16/2022]
|
52
|
Romain B, Mielcarek M, Delhorme JB, Meyer N, Brigand C, Rohr S. Dialkylcarbamoyl chloride-coated versus alginate dressings after pilonidal sinus excision: a randomized clinical trial (SORKYSA study). BJS Open 2020; 4:225-231. [PMID: 32020765 PMCID: PMC7093794 DOI: 10.1002/bjs5.50259] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/17/2019] [Accepted: 12/16/2019] [Indexed: 11/20/2022] Open
Abstract
Background Disease of the pilonidal sinus is a common condition that affects mainly young adults. Options for management include excision of the sinus tracts, leaving the wound open to heal by secondary intention. The aim of this study was to compare wound healing with dialkylcarbamoyl chloride (DACC)‐coated dressings versus alginate dressings. Methods This multicentre trial randomized consecutive patients undergoing surgery for pilonidal disease to postoperative wound care with either DACC‐coated or alginate dressings. The primary outcome was the proportion of wounds healed after 75 days. Secondary outcomes were the local status of wounds during the healing process, the quality assessment of the dressings by the patient, and the time needed to return to usual activities. Results A total of 246 patients were included: 120 in the DACC‐coated group and 126 in the alginate group. In per‐protocol analysis, there were significantly more patients with completely healed wounds after 75 days in the DACC group than in the alginate group: 78 of 103 (75·7 per cent) versus 58 of 97 (60 per cent) respectively (odds ratio 2·55, 95 per cent c.i. 1·12 to 5·92; P = 0·023). During follow‐up, wounds with alginate dressings had more fibrin than those with DACC‐coated dressings, but the difference was not significant (P = 0·079). There was no difference between the two arms in patients' assessment of the dressings. Conclusion The number of wounds completely healed at 75 days was significantly higher for DACC‐coated compared with alginate dressings. However, the preplanned, clinically significant improvement in healing of 20 per cent was not reached. Registration number: NCT02011802 (
https://clinicaltrials.gov/).
Collapse
|
53
|
Rahal A, Ruch Y, Meyer N, Perrier S, Hoang Minh T, Schneider C, Lavigne T, Marguerite S, Ajob G, Cristinar M, Epailly E, Mazzucotelli JP, Kindo M. Infections associées aux assistances ventriculaires gauches : incidence et facteurs de risques. Rev Epidemiol Sante Publique 2020. [DOI: 10.1016/j.respe.2019.11.015] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022] Open
|
54
|
Maubec E, Boubaya M, Petrow P, Basset-Seguin N, Grob JJ, Dréno B, Beylot-Barry M, Scheer-Senyarich I, Helfen S, Deschamps L, Leccia MT, Stefan A, Saiag P, De Quatrebarbes J, Meyer N, Alloux C, Lopez I, Cherbal S, Tibi A, Levy V. Étude de phase II de l’administration de pembrolizumab (MK-3475) en monothérapie et en première ligne chez des patients présentant un carcinome épidermoïde cutané non opérable. Ann Dermatol Venereol 2019. [DOI: 10.1016/j.annder.2019.09.092] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
55
|
Meyer N, Faulkner S, McCutcheon R, Pillinger T, Dijk DJ, MacCabe J. Transdiagnostic sleep and circadian rhythm disturbance in schizophrenia and bipolar disorder: a systematic review and meta-analysis. Sleep Med 2019. [DOI: 10.1016/j.sleep.2019.11.709] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
56
|
Varey E, Dalle S, Dupuy A, Montaudié H, Guillot B, Mortier L, Leccia MT, Célérier P, Skowron F, Meyer N, Maubec E, Combemale P, Crickx B, Dalac-Rat S, Dutriaux C, Khammari A, Lebbé C, Dréno B. Patients présentant un mélanome acro-lentigineux inclus dans la base nationale RIC-Mel. Ann Dermatol Venereol 2019. [DOI: 10.1016/j.annder.2019.09.103] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
57
|
Touhouche A, Pages C, Sibaud V, Florian D, Boulinguez S, Meyer N. Réponse exceptionnelle à la chimiothérapie après immunothérapie première chez 3 patients atteints de mélanome stade IV. Ann Dermatol Venereol 2019. [DOI: 10.1016/j.annder.2019.09.507] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
58
|
Salomon G, Severino M, Casassa E, Bulai Livideanu C, Meyer N, Lamant L, Tournier E, Paul C. Les manifestations cutanées du syndrome hyperéosinophilique sont polymorphes et difficiles à traiter : étude de cohorte rétrospective. Ann Dermatol Venereol 2019. [DOI: 10.1016/j.annder.2019.09.481] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
59
|
Meyer N, Joyce D, Karr C, van Hees V, Faulkner S, Dijk DJ, MacCabe J, de Vos M, Skeldon A. Desynchronisation of sleep-wake rhythms in schizophrenia: a theoretical intervention framework. Sleep Med 2019. [DOI: 10.1016/j.sleep.2019.11.708] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
60
|
Grob JJ, Mortier L, Dutriaux C, Benmahammed L, Morsli O, Train C, Spampinato A, Leccia M, Meyer N, Saiag P. Patients atteints de mélanome avancé ayant arrêté le pembrolizumab (pembro) après une réponse complète (RC), pendant son Autorisation Temporaire d’Utilisation (ATU). Ann Dermatol Venereol 2019. [DOI: 10.1016/j.annder.2019.09.024] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
61
|
Saiag P, Meyer N, Dutriaux C, Benmahammed L, Morsli O, Spampinato A, Fayette JM, Mortier L, Grob JJ. Facteurs associés à la progression/survie – Arbres de régression : étude de suivi de cohorte de 5 ans des patients ayant initié le pembrolizumab en traitement de leur mélanome avancé pendant son ATU. Ann Dermatol Venereol 2019. [DOI: 10.1016/j.annder.2019.09.111] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
62
|
Perrett KP, Halperin SA, Nolan T, Carmona Martínez A, Martinón-Torres F, García-Sicilia J, Virta M, Vanderkooi OG, Zuccotti GV, Manzoni P, Kostanyan L, Meyer N, Ceregido MA, Cheuvart B, Kuriyakose SO, Stranak Z, Merino Arribas JM, Cilleruelo Ortega MJ, Miranda-Valdivieso M, Arias Novas B, Ramos Amador JT, Omeñaca F, Baca M, Marchisio PG, Mesaros N. Impact of tetanus-diphtheria-acellular pertussis immunization during pregnancy on subsequent infant immunization seroresponses: follow-up from a large randomized placebo-controlled trial. Vaccine 2019; 38:2105-2114. [PMID: 31776027 DOI: 10.1016/j.vaccine.2019.10.104] [Citation(s) in RCA: 19] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/07/2019] [Revised: 10/30/2019] [Accepted: 10/31/2019] [Indexed: 11/16/2022]
Abstract
BACKGROUND Pertussis immunization during pregnancy results in high pertussis antibody concentrations in young infants but may interfere with infant immune responses to post-natal immunization. METHODS This phase IV, multi-country, open-label study assessed the immunogenicity and safety of infant primary vaccination with DTaP-HepB-IPV/Hib and 13-valent pneumococcal conjugate vaccine (PCV13). Enrolled infants (6-14 weeks old) were born to mothers who were randomized to receive reduced-antigen-content diphtheria-tetanus-three-component acellular pertussis vaccine (Tdap group) or placebo (control group) during pregnancy (270/7-366/7 weeks' gestation) with crossover immunization postpartum. All infants received 2 or 3 DTaP-HepB-IPV/Hib and PCV13 doses according to national schedules. Immunogenicity was assessed in infants pre- and 1 month post-primary vaccination. The primary objective was to assess seroprotection/vaccine response rates for DTaP-HepB-IPV/Hib antigens 1 month post-primary vaccination. RESULTS 601 infants (Tdap group: 296; control group: 305) were vaccinated. One month post-priming, seroprotection rates were 100% (diphtheria; tetanus), ≥98.5% (hepatitis B), ≥95.9% (polio) and ≥94.5% (Hib) in both groups. Vaccine response rates for pertussis antigens were significantly lower in infants whose mothers received pregnancy Tdap (37.5-77.1%) versus placebo (90.0-99.2%). Solicited and unsolicited adverse event rates were similar between groups. Serious adverse events occurred in 2.4% (Tdap group) and 5.6% (control group) of infants, none were vaccination-related. CONCLUSIONS Pertussis antibodies transferred during pregnancy may decrease the risk of pertussis infection in the first months of life but interfere with the infant's ability to produce pertussis antibodies, the clinical significance of which remains unknown. Safety and reactogenicity results were consistent with previous experience. CLINICAL TRIAL REGISTRATION ClinicalTrials.gov: NCT02422264.
Collapse
|
63
|
de Lusignan S, Correa A, Dos Santos G, Meyer N, Haguinet F, Webb R, McGee C, Byford R, Yonova I, Pathirannehelage S, Ferreira FM, Jones S. Enhanced Safety Surveillance of Influenza Vaccines in General Practice, Winter 2015-16: Feasibility Study. JMIR Public Health Surveill 2019; 5:e12016. [PMID: 31724955 PMCID: PMC6913774 DOI: 10.2196/12016] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/23/2018] [Revised: 11/23/2018] [Accepted: 03/22/2019] [Indexed: 12/01/2022] Open
Abstract
Background The European Medicines Agency (EMA) requires vaccine manufacturers to conduct enhanced real-time surveillance of seasonal influenza vaccination. The EMA has specified a list of adverse events of interest to be monitored. The EMA sets out 3 different ways to conduct such surveillance: (1) active surveillance, (2) enhanced passive surveillance, or (3) electronic health record data mining (EHR-DM). English general practice (GP) is a suitable setting to implement enhanced passive surveillance and EHR-DM. Objective This study aimed to test the feasibility of conducting enhanced passive surveillance in GP using the yellow card scheme (adverse events of interest reporting cards) to determine if it has any advantages over EHR-DM alone. Methods A total of 9 GPs in England participated, of which 3 tested the feasibility of enhanced passive surveillance and the other 6 EHR-DM alone. The 3 that tested EPS provided patients with yellow (adverse events) cards for patients to report any adverse events. Data were extracted from all 9 GPs’ EHRs between weeks 35 and 49 (08/24/2015 to 12/06/2015), the main period of influenza vaccination. We conducted weekly analysis and end-of-study analyses. Results Our GPs were largely distributed across England with a registered population of 81,040. In the week 49 report, 15,863/81,040 people (19.57% of the registered practice population) were vaccinated. In the EPS practices, staff managed to hand out the cards to 61.25% (4150/6776) of the vaccinees, and of these cards, 1.98% (82/4150) were returned to the GP offices. Adverse events of interests were reported by 113 /7223 people (1.56%) in the enhanced passive surveillance practices, compared with 322/8640 people (3.73%) in the EHR-DM practices. Conclusions Overall, we demonstrated that GPs EHR-DM was an appropriate method of enhanced surveillance. However, the use of yellow cards, in enhanced passive surveillance practices, did not enhance the collection of adverse events of interests as demonstrated in this study. Their return rate was poor, data entry from them was not straightforward, and there were issues with data reconciliation. We concluded that customized cards prespecifying the EMA’s adverse events of interests, combined with EHR-DM, were needed to maximize data collection. International Registered Report Identifier (IRRID) RR2-10.1136/bmjopen-2016-015469
Collapse
|
64
|
Dupont R, Bérard E, Puisset F, Comont T, Delord JP, Guimbaud R, Meyer N, Mazieres J, Alric L. The prognostic impact of immune-related adverse events during anti-PD1 treatment in melanoma and non-small-cell lung cancer: a real-life retrospective study. Oncoimmunology 2019; 9:1682383. [PMID: 32002292 PMCID: PMC6959447 DOI: 10.1080/2162402x.2019.1682383] [Citation(s) in RCA: 32] [Impact Index Per Article: 6.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/05/2019] [Revised: 10/14/2019] [Accepted: 10/14/2019] [Indexed: 12/26/2022] Open
Abstract
Background: Nivolumab and pembrolizumab, two PD1 inhibitors, trigger immune-related adverse events in approximately 50% of patients. Our objective was to determine whether these immune-related adverse events are associated with patient outcomes. Patients and Methods: Retrospective cohort study, realized at the Institut Universitaire du Cancer de Toulouse, of all the patients treated with nivolumab or pembrolizumab off clinical trials. We included patients (i) diagnosed with unresectable stage III or stage IV melanoma or with recurrent stage IIIB or stage IV non-small cell lung cancer (ii) on nivolumab 3mg/kg or pembrolizumab 2mg/kg every 2 or 3 weeks respectively. Results: Of the 311 patients included (of 641 eligible subjects), 120 (38.6%) had melanoma and 191 (61.4%) had non-small cell lung cancer; 241 (77.5%) were treated with nivolumab with a median follow-up of 24 months (20-29). We observed 166 immune-related adverse events in 116 (37.3%) patients, categorized as "early" (onset before 12 weeks in melanoma and before 8 weeks in lung cancer) in 63 (54.3%) patients. Early and late adverse events were significantly associated with an increase in overall survival: adjusted hazard ratio 0.58 [0.41-0.84] (p = .003) and 0.28 [0.16-0.50] (p < .001) respectively. The overall response rate was significantly increased in patients with an immune-related adverse event (53.9% vs 12.9%, p < .001) Conclusions: This study validates the association between immune-related adverse events and anti-PD1 efficacy in real-life, especially if these events are delayed. Our results, along with further studies on the place of immunosuppressive drugs in the therapeutic strategy, could improve the management of these adverse events.
Collapse
|
65
|
Comont T, Belliere J, Sibaud V, Alric L, Meyer N, Mazières J, Caron P, Acket B, Michot JM, Beyne-Rauzy O, Lambotte O. [Immune-related adverse events after immune checkpoints inhibitors in 2019: An update]. Rev Med Interne 2019; 41:37-45. [PMID: 31668882 DOI: 10.1016/j.revmed.2019.09.005] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/17/2019] [Revised: 09/23/2019] [Accepted: 09/26/2019] [Indexed: 12/11/2022]
Abstract
Use of checkpoint inhibitors to treat cancer was one of the most important revolution these last years and an increasing number of new types of tumors is currently under investigation with these new treatments. However, immune-related adverse events associated with these agents frequently affect various organs, mimicking auto-immune or inflammatory diseases. Some of these effects can be severe, often requiring hospitalization and specialized treatment (immunosuppression). Most known agents are ipilimumab (anti-CTLA-4 antibody) nivolumab and pembrolizumab (anti-PD-1 antibodies). New molecules are now approved or in development as anti-PD-L1 antibodies, anti-LAG-3 or anti-TIM-3 antibodies, increasing the probability and new description of immune-related adverse events. With his experience in auto-immune diseases, the immunologist/internal medicine specialist has an important role in the management of these toxicities. The goal of this review is to focus on the incidence, diagnostic assessment and recommended management of the most relevant immune-related adverse events.
Collapse
|
66
|
Saiag P, Mortier L, Dutriaux C, Benmahammed L, Morsli O, Train C, Spampinato A, Leccia M, Meyer N, Grob J. Outcomes of advanced melanoma patients who discontinued pembrolizumab (pembro) after complete response (CR) in the French early access program (EAP). Ann Oncol 2019. [DOI: 10.1093/annonc/mdz255.033] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
67
|
Grob J, Gonzalez Mendoza R, Basset-Seguin N, Vornicova O, Schachter J, Joshi A, Meyer N, Grange F, Piulats J, Bauman J, Zhang P, Gumuscu B, Swaby R, Hughes B. Pembrolizumab for recurrent/metastatic cutaneous squamous cell carcinoma (cSCC): Efficacy and safety results from the phase II KEYNOTE-629 study. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz394.069] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
68
|
Modesto A, Dalmasso C, Chaltiel L, Pagès C, Boulinguez S, Sibaud V, Chira C, Latorzeff I, Lubrano V, Moyal É, Meyer N. Le traitement local intracrânien des métastases cérébrales de mélanome allonge la survie globale des patients pris en charge par immunothérapie ou anti-Braf. Cancer Radiother 2019. [DOI: 10.1016/j.canrad.2019.07.058] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
69
|
Desrousseaux J, Cabarrou B, Modesto A, Rives M, Parent L, Brun T, Tournier A, Arnaud F, Meyer N, Sibaud V, Pages C, Boulinguez S, Gangloff D, Chira C. Electronic Brachytherapy for Skin Carcinomas of the Face : Practical Considerations from a Retrospective Series of 53 Lesions. Int J Radiat Oncol Biol Phys 2019. [DOI: 10.1016/j.ijrobp.2019.06.1555] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
70
|
Schröder-Heurich B, von Hardenberg S, Brodowski L, Kipke B, Meyer N, Borns K, von Kaisenberg CS, Brinkmann H, Claus P, von Versen-Höynck F. Vitamin D improves endothelial barrier integrity and counteracts inflammatory effects on endothelial progenitor cells. FASEB J 2019; 33:9142-9153. [PMID: 31084577 DOI: 10.1096/fj.201802750rr] [Citation(s) in RCA: 16] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022]
Abstract
Endothelial colony-forming cells (ECFCs), a proliferative subpopulation of endothelial progenitor cells, are involved in angiogenesis and endothelial repair. In this study, we investigated endothelial barrier characteristics of ECFCs, whether vitamin D supports cell-cell adhesion and barrier integrity, and how it affects ECFC mobilization and actin dynamics. Although ECFC barrier was disrupted under inflammatory conditions, this effect was rescued by vitamin D treatment, leading to higher stability of an ECFC monolayer. Furthermore, vitamin D enhanced ECFC mobilization toward directional migration. In addition, immunocytochemistry, quantitative real-time PCR, and immunoblotting analysis showed that vitamin D increased endothelial interconnections through vascular endothelial cadherin (VE-cadherin) junctions and by impacting cell dynamics through cofilin and VE-cadherin phosphorylation. Our results suggest that vitamin D treatment efficiently counteracts inflammation in an ECFC monolayer, resulting in higher ECFC barrier integrity. This study provides evidence of a new beneficial effect of vitamin D for ECFC homeostasis.-Schröder-Heurich, B., von Hardenberg, S., Brodowski, L., Kipke, B., Meyer, N., Borns, K., von Kaisenberg, C. S., Brinkmann, H., Claus, P., von Versen-Höynck, F. Vitamin D improves endothelial barrier integrity and counteracts inflammatory effects on endothelial progenitor cells.
Collapse
|
71
|
Meyer N, Xu H, Wax JF. The role of chemical order in the temperature and composition dependence of the viscosity of liquid alloys. J Chem Phys 2019; 150:174502. [PMID: 31067875 DOI: 10.1063/1.5092694] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
The influence of the chemical order on the viscosity of liquid alloys is investigated by numerical simulation of molecular dynamics. The temperature and composition dependence is discussed in the case of two contrasting alloys: K-Cs and Li-Bi. These two mixtures have different chemical orders, the first one being random and the second one having strong heterocoordination tendencies. In the case of K-Cs, the behavior of the mixture vs temperature is similar to a pure system and its viscosity varies monotonically with the composition. It is not the case for Li-Bi due to its marked chemical order and the heterocoordination tendency is accompanied by a maximum of the viscosity of the mixture when the composition is changed. For the first time, estimates of the temperature dependence of the viscosity of three representative Li-Bi alloys are given.
Collapse
|
72
|
Ferreira D, Vivot A, Meyer N. Méthodes bayésiennes dans les essais contrôlés randomisés de phase III : une revue systématique. Rev Epidemiol Sante Publique 2019. [DOI: 10.1016/j.respe.2019.03.011] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
|
73
|
Ferreira D, Barthoulot M, Pottecher J, Diemunsch P, Meyer N. Une checklist pour les essais cliniques analysés en Bayésien. Rev Epidemiol Sante Publique 2019. [DOI: 10.1016/j.respe.2019.03.012] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
|
74
|
Modesto A, Chira C, Sol JC, Lubrano V, Boulinguez S, Pagès C, Sibaud V, Gomez-Roca C, Moyal É, Meyer N. Prise en charge des patients atteints de métastases cérébrales de mélanome. Cancer Radiother 2019. [DOI: 10.1016/j.canrad.2019.03.002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
75
|
Modesto A, Chira C, Sol JC, Lubrano V, Boulinguez S, Pagès C, Sibaud V, Gomez-Roca C, Moyal É, Meyer N. Prise en charge des patients atteints de métastases cérébrales de mélanome. Cancer Radiother 2019; 23:147-150. [DOI: 10.1016/j.canrad.2018.05.006] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/22/2018] [Revised: 05/15/2018] [Accepted: 05/17/2018] [Indexed: 11/29/2022]
|
76
|
Modesto A, Chira C, Sol JC, Lubrano V, Boulinguez S, Pagès C, Sibaud V, Gomez-Roca C, Moyal É, Meyer N. Prise en charge des patients atteints de métastases cérébrales de mélanome. Cancer Radiother 2019. [DOI: 10.1016/j.canrad.2019.03.004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
77
|
Santamaría C, Abud J, Porporato M, Meyer N, Zenclussen A, Kass L, Rodríguez H. The UV filter benzophenone 3, alters early follicular assembly in rat whole ovary cultures. Toxicol Lett 2019; 303:48-54. [DOI: 10.1016/j.toxlet.2018.12.016] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/24/2018] [Revised: 12/20/2018] [Accepted: 12/28/2018] [Indexed: 10/27/2022]
|
78
|
Borne E, Meyer N, Rybarczyck-Vigouret MC, Blanchard O, Lombard M, Lang PO, Vogel T, Michel B. Prescriptions potentiellement inappropriées de statines chez les sujets âgés : analyse à partir des bases de données de l’Assurance maladie. Rev Epidemiol Sante Publique 2019. [DOI: 10.1016/j.respe.2018.11.008] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
|
79
|
Dagrenat C, Von Hunolstein J, Thebaud L, Marchandot B, Messas N, Greciano S, Tuzin N, Meyer N, Trinh A, Jesel L, Ohlmann P, Morel O. Value of cardiac biomarkers in the early diagnosis of Takotsubo syndrome. ARCHIVES OF CARDIOVASCULAR DISEASES SUPPLEMENTS 2019. [DOI: 10.1016/j.acvdsp.2018.10.318] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
80
|
Dupont R, Berard E, Puisset F, Comont T, Guimbaud R, Meyer N, Mazieres J, Alric L. Colite ou hépatite immunologiques au cours du traitement par nivolumab et du pembrolizumab pour un mélanome ou un cancer bronchique : un facteur de bon pronostic. Rev Med Interne 2018. [DOI: 10.1016/j.revmed.2018.10.187] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
81
|
Dupont R, Berard E, Puisset F, Fort M, Comont T, Guimbaud R, Meyer N, Mazieres J, Alric L. Facteurs prédictifs de survenue des effets indésirables immunologiques au cours du traitement du mélanome et du cancer bronchique par inhibiteurs de check point. Rev Med Interne 2018. [DOI: 10.1016/j.revmed.2018.10.338] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
82
|
Gerard E, Dupuis F, Lamant L, Torossian N, Chaltiel L, Filleron T, Beylot-Barry M, Dutriaux C, Prey S, Gros A, Jullie ML, Meyer N, Vergier B. Évaluation des critères cliniques, pathologiques et moléculaires prédictifs de réponse à l’immunothérapie anti-PD1 dans le mélanome métastatique : analyse rétrospective de 70 patients. Ann Dermatol Venereol 2018. [DOI: 10.1016/j.annder.2018.09.099] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
83
|
Varey E, Thomas L, Dalle S, Lesimple T, Lacour JP, Guillot B, Mortier L, Leccia MT, Skowron F, Celerier P, Meyer N, Combemale P, Crickx B, Dutriaux C, Dalac-Rat S, Khammari A, Lebbé C, Dréno B. Développement des nouveaux traitements en situation adjuvante du mélanome : données épidémiologiques de la base RIC-Mel. Ann Dermatol Venereol 2018. [DOI: 10.1016/j.annder.2018.09.499] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
84
|
Fradet M, Bulai-Livideanu C, Lamant L, Tournier E, Laurent C, Apoil PA, Meyer N, Sibaud V. Deux cas d’urticaire pigmentaire radio-induite révélant une mastocytose systémique. Ann Dermatol Venereol 2018. [DOI: 10.1016/j.annder.2018.09.479] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
85
|
Chaplain L, Blom A, Samimi M, Guillot B, Jouary T, Grob JJ, Meyer N, Zehou O, Combemale P, Lebbé C, Jeudy G, Grange F, Lacour P, Dinulescu M, Granel Brocard F, Beneton N, Aubin F, Bens G, De Quatrebarbes J, Steff M, Arnault JP, Le Corre Y, Stefan A, D’Incan M, Kramkimel N, Leccia MT, Thomas Beaulieu D, Maubec E, Robert C, Dreno B, Wierzbicka-Hainaut E, Lenormand C, Saiag P, Mortier L. Carcinome de Merkel : état des lieux du réseau CARADERM. Ann Dermatol Venereol 2018. [DOI: 10.1016/j.annder.2018.09.141] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
86
|
Delyon J, Porcher R, Battistella M, Meyer N, Adamski H, Bertucci F, Guillot B, Jouary T, Leccia MT, Dalac S, Mortier L, Vicaut E, Pedeutour F, Mourah S, Lebbe C. Essai de phase II multicentrique évaluant le pazopanib dans le traitement du dermatofibrosarcome non opérable ou récidivant. Ann Dermatol Venereol 2018. [DOI: 10.1016/j.annder.2018.09.148] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
87
|
Raynal M, Lheure C, Seta V, Chanal J, Franck N, Sarah G, Dupin N, Aractingi S, Meyer N, Kramkimel N. Traitement de mélanomes métastatiques avec mutation de NRAS par inhibiteur de MEK après échec de l’immunothérapie. Ann Dermatol Venereol 2018. [DOI: 10.1016/j.annder.2018.09.496] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
88
|
Deilhes F, Pagès C, Guillemette S, Sibaud V, Regnault MM, Tournier E, Meyer N. Xeroderma pigmentosum : un nouveau cas d’efficacité des anticorps anti-PD1 dans le traitement d’un mélanome non résécable et de multiples proliférations épithéliales cutanées. Ann Dermatol Venereol 2018. [DOI: 10.1016/j.annder.2018.09.250] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
89
|
Dupont R, Berard E, Puisset F, Comont T, Guimbaud R, Meyer N, Mazieres J, Alric L. Éffets indésirables immunologiques du nivolumab et du pembrolizumab dans le mélanome et le cancer bronchique : implications pronostiques dans une étude rétrospective de vie réelle. Rev Med Interne 2018. [DOI: 10.1016/j.revmed.2018.10.337] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
90
|
Saiag P, Mortier L, Dutriaux C, Benmahammed L, Leccia MT, Meyer N. Impact d’une radiothérapie concomitante du mélanome avancé traité par pembrolizumab : étude française au sein du programme national d’accès précoce. Ann Dermatol Venereol 2018. [DOI: 10.1016/j.annder.2018.09.528] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
91
|
Faviez G, Bousquet E, Rabeau A, Rouquette I, Collot S, Goumarre C, Meyer N, Prevot G, Mazieres J. Granulomatose sarcoïdosique survenant sous inhibiteurs de point de contrôle immunitaire. Rev Mal Respir 2018; 35:963-967. [DOI: 10.1016/j.rmr.2018.08.003] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/31/2017] [Accepted: 11/14/2017] [Indexed: 11/29/2022]
|
92
|
Meyer N, Schröder-Heurich B, Kaisenberg CS, Melk A, Schmidt B, Versen-Höynck F. Impact of immunosuppression on endothelial progenitor cell capacity in pregnancy. Geburtshilfe Frauenheilkd 2018. [DOI: 10.1055/s-0038-1671204] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022] Open
|
93
|
Steinmetz S, Puliero B, Brinkert D, Meyer N, Adam P, Bonnomet F, Ehlinger M. Erratum to "Tibiofemoral syndesmosis injury treated by temporary screw fixation and ligament repair" [Orthop. Traumatol. Surg. Res. 102 (2016) 1069-1073]. Orthop Traumatol Surg Res 2018; 104:939. [PMID: 30122308 DOI: 10.1016/j.otsr.2018.07.004] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
|
94
|
Mignard C, Deschamps-Huvier A, Duval-Modeste AB, Dutriaux C, Khammari A, Avril MF, Mortier L, Lesimple T, Gaudy-Marqueste C, Lesage C, Machet L, Aubin F, Meyer N, Beneton Benhard N, Jeudy G, Montaudié H, Arnault JP, Leccia MT, Joly P, Oncology Research Group Of The French Society Of Dermatology S. Efficacy of immunotherapy in patients with metastatic mucosal or uveal melanoma. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy289.026] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
95
|
Lebbé C, Meyer N, Mortier L, Marquez-Rodas I, Robert C, Rutkowski P, Menzies A, Eigentler T, Ascierto P, Smylie M, Ajaz M, Svane IM, Gonzalez R, Rollin L, Saci A, Grigoryeva E, Pigozzo J. Initial results from a phase IIIb/IV study evaluating two dosing regimens of nivolumab (NIVO) in combination with ipilimumab (IPI) in patients with advanced melanoma (CheckMate 511). Ann Oncol 2018. [DOI: 10.1093/annonc/mdy424.057] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
96
|
Nason GJ, Selvarajah L, O’Connor EM, O’Kelly J, Considine SW, Moss B, MacMahon D, Heneghan J, Meyer N, Buckley J, O’Regan K, O’Brien MF. The Predictive Ability of Pre-Operative Magnetic Resonance Imaging to Detect Pathological Outcomes in Prostate Cancer. IRISH MEDICAL JOURNAL 2018; 111:790. [PMID: 30520617] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Subscribe] [Scholar Register] [Indexed: 06/09/2023]
Abstract
Aims Accurate preoperative knowledge of tumour stage is important in preoperative planning at radical prostatectomy (RP). The aim of this study was to assess the predictive ability of multiparametric MRI for detecting pathological outcomes. Methods A retrospective review was performed of all patients who underwent RP over a 4 year period. Results Preoperative MRI was reported as showing T3 or T4 disease in 26(17.9%) out of 145 patients undergoing RP. Of these, 10(6.9%) had ECE (extra-capsular extension) and 1(0.7%) had SVI (seminal vesicle invasion) on final histology. The sensitivity and specificity of MRI for detecting ECE were 27.3% and 87.6%, respectively. The sensitivity and specificity of MRI for detecting SVI were 11.1% and 97.8%, respectively. The positive predictive values for determining ECE and SVI were 45.5% and 25%, respectively and negative predictive values were 75.9% and 94.4%. Conclusion MRI has good specificity but poor and heterogeneous sensitivity for predicting T3 disease in RP specimen.
Collapse
|
97
|
Romain B, Gillion JF, Ortega-Deballon P, Meyer N. Patient's satisfaction at 2 years after groin hernia repair: any difference according to the technique? Hernia 2018; 22:801-812. [PMID: 29971566 DOI: 10.1007/s10029-018-1796-y] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/26/2018] [Accepted: 06/22/2018] [Indexed: 11/29/2022]
Abstract
BACKGROUND Long-term patient's satisfaction after groin hernia repair is rarely studied in the literature. The aim of this study was to compare the four main techniques of inguinal hernia repair in terms of patient's satisfaction and quality of life at the 2-year follow-up in a prospective registry. METHODS From September 2011 to March 2014, consecutive patients underwent groin hernia repair and were prospectively included in the Club Hernie registry, which also consisted of expert surgeons in parietal repair. The data on patient demographics, clinical presentation, initial workup, operative technique, postoperative course, clinical follow-up, and quality of life at 2 years (2Y-FU) were recorded. RESULTS Overall, 5670 patients were included in the study: 1092 undergoing Lichtenstein's technique, 1259 for trans-inguinal preperitoneal technique (TIPP), 1414 for totally extraperitoneal approach (TEP) and 1905 for transabdominal preperitoneal approach (TAPP). The patients undergoing Lichtenstein's technique were significantly older, with more inguinoscrotal hernias and co-morbidities than those undergoing other techniques. A total of 83% patients had a complete 2Y-FU. The patient's satisfaction at 2Y-FU was similar between the different techniques. In the univariate and multivariate analyses, pain on postoperative day 1 was the only independent prognostic factor of the patient's satisfaction at 2Y-FU. CONCLUSION In this large series, no statistical differences were found between the four studied techniques regarding the 2Y-Fu results and patients' satisfaction. Provided the technique has been done properly (expert surgeon) the results and the patients' satisfaction are fair and equivalent among the four studied techniques. In a multivariate analysis, the only factor predictive of bad late results was severe pain at D1.
Collapse
|
98
|
Goussot R, Francès C, Cury K, Bessis D, Martin T, Chatelus E, Mahé A, Messer L, Séverac F, Meyer N, Lipsker D. Prospective evaluation of the frequency of genital lichen sclerosus in 79 patients with systemic sclerosis. Br J Dermatol 2018; 179:999-1000. [PMID: 29928761 DOI: 10.1111/bjd.16898] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
99
|
Meyer N, Wax JF, Xu H. Viscosity of Lennard-Jones mixtures: A systematic study and empirical law. J Chem Phys 2018; 148:234506. [PMID: 29935509 DOI: 10.1063/1.5034779] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
A systematic study of the viscosity of the binary Lennard-Jones (LJ) mixtures is carried out by equilibrium molecular dynamics simulations via the Green-Kubo relation. The effects of mass, size, and energy-parameter asymmetries on the viscosity and the self-diffusion coefficients are examined separately, both in equimolar mixtures and by varying the molar fractions. The systems are mapped into an effective one-component model according to the van der Waals one-fluid (vdW1) model. Furthermore, using an empirical law for pure LJ liquids, similar to the one proposed recently for liquid sodium, it is shown that the viscosity of the mixtures studied here are well-predicted by the combination of vdW1 fluid and empirical law. The Stokes-Einstein relation in the mixtures has also been investigated. A possible simple extension of this relation, from pure liquids to mixtures, has been proposed and tested.
Collapse
|
100
|
Durden E, Lenhart G, Meyer N, Shenolikar R, Moore K. Duration of exposure to select DNA-damaging therapy and the risk of secondary myelodysplastic syndrome and acute myeloid leukemia in patients with ovarian or breast cancer in a real-world setting in the United States. Gynecol Oncol 2018. [DOI: 10.1016/j.ygyno.2018.04.348] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|